↓ Skip to main content

Evidence-based clinical use of insulin premixtures

Overview of attention for article published in Diabetology & Metabolic Syndrome, September 2013
Altmetric Badge

Mentioned by

twitter
1 X user

Readers on

mendeley
44 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Evidence-based clinical use of insulin premixtures
Published in
Diabetology & Metabolic Syndrome, September 2013
DOI 10.1186/1758-5996-5-50
Pubmed ID
Authors

Marcos Antônio Tambascia, Márcia Nery, Jorge Luiz Gross, Mariana Narbot Ermetice, Carolina Piras de Oliveira

Abstract

Brazil is expected to have 19.6 million patients with diabetes by the year 2030. A key concept in the treatment of type 2 diabetes mellitus (T2DM) is establishing individualized glycemic goals based on each patient's clinical characteristics, which impact the choice of antihyperglycemic therapy. Targets for glycemic control, including fasting blood glucose, postprandial blood glucose, and glycated hemoglobin (A1C), are often not reached solely with antihyperglycemic therapy, and insulin therapy is often required. Basal insulin is considered an initial strategy; however, premixed insulins are convenient and are equally or more effective, especially for patients who require both basal and prandial control but desire a more simplified strategy involving fewer daily injections than a basal-bolus regimen. Most physicians are reluctant to transition patients to insulin treatment due to inappropriate assumptions and insufficient information. We conducted a nonsystematic review in PubMed and identified the most relevant and recently published articles that compared the use of premixed insulin versus basal insulin analogues used alone or in combination with rapid-acting insulin analogues before meals in patients with T2DM. These studies suggest that premixed insulin analogues are equally or more effective in reducing A1C compared to basal insulin analogues alone in spite of the small increase in the risk of nonsevere hypoglycemic events and nonclinically significant weight gain. Premixed insulin analogues can be used in insulin-naïve patients, in patients already on basal insulin therapy, and those using basal-bolus therapy who are noncompliant with blood glucose self-monitoring and titration of multiple insulin doses. We additionally provide practical aspects related to titration for the specific premixed insulin analogue formulations commercially available in Brazil.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 44 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 44 100%

Demographic breakdown

Readers by professional status Count As %
Student > Postgraduate 5 11%
Researcher 4 9%
Professor 4 9%
Student > Bachelor 4 9%
Student > Master 4 9%
Other 10 23%
Unknown 13 30%
Readers by discipline Count As %
Medicine and Dentistry 15 34%
Pharmacology, Toxicology and Pharmaceutical Science 6 14%
Nursing and Health Professions 2 5%
Neuroscience 2 5%
Biochemistry, Genetics and Molecular Biology 1 2%
Other 4 9%
Unknown 14 32%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 September 2013.
All research outputs
#18,345,822
of 22,719,618 outputs
Outputs from Diabetology & Metabolic Syndrome
#461
of 660 outputs
Outputs of similar age
#146,654
of 197,012 outputs
Outputs of similar age from Diabetology & Metabolic Syndrome
#11
of 17 outputs
Altmetric has tracked 22,719,618 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 660 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.2. This one is in the 15th percentile – i.e., 15% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 197,012 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 12th percentile – i.e., 12% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 17 others from the same source and published within six weeks on either side of this one. This one is in the 11th percentile – i.e., 11% of its contemporaries scored the same or lower than it.